Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | CASR | P41180 | 3/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 3/20 | 0.39 |
| ▸ | WDR48 | Q8TAF3 | 3/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922348 | 0.90 | PDE4B (0.50) | PDE4BCASRUSP1WDR48GALR3 | |
| SCHEMBL13868177 | 0.88 | CASR (0.51) | PDE4BCASRUSP1WDR48 | |
| SCHEMBL3920333 | 0.84 | CASR (0.53) | PDE4BCASR | |
| SCHEMBL3922139 | 0.84 | PTGES (0.49) | CASRPTGESUSP1WDR48 | |
| SCHEMBL3932544 | 0.83 | USP1 (0.43) | CASRPTGESUSP1WDR48 | |
| SCHEMBL3920463 | 0.80 | CASR (0.58) | PDE4BCASR | |
| SCHEMBL13868197 | 0.79 | CASR (0.53) | PDE4BCASR | |
| SCHEMBL2461120 | 0.77 | LOXL2 (0.48) | CASR | |
| SCHEMBL3932217 | 0.77 | CASR (0.47) | CASR | |
| SCHEMBL3922202 | 0.76 | CASR (0.48) | CASRPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | claimed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | claimed |
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | PDE4B 656/4885CASR 2/4885PTGES 1082/4885 |
| US-20070142381-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | PDE4B 653/4885CASR 2/4885PTGES 1036/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | PDE4B 364/4885CASR 24/4885PTGES 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.